Lack of interaction between meloxicam and warfarin in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 51, Issue 5, 1997, Pages 421-425

  Turck D ^a   Su, C A P F ^a   Heinzel, G ^a   Busch, U ^a   Bluhmki, E ^a   Hoffmann, J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Interaction; Meloxicam; Pharmacokinetics; Protein binding; Warfarin

Indexed keywords

MELOXICAM; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG INTERACTION; DRUG PROTEIN BINDING; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTHROMBIN TIME; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; DRUG INTERACTIONS; HUMANS; MALE; PROTEIN BINDING; STEREOISOMERISM; THIAZINES; THIAZOLES; WARFARIN;

EID: 0031015554     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050224     Document Type: Article

References (32)

1. Engelhardt G, Homma D, Schlegel K, Schnitzler Chr, Utzmann R (1995) Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44: 423-433
2. Engelhardt G, Bögel R, Schnitzer Chr, Utzmann R (1996) Meloxicam: Influence on arachidonic acid metabolism. Part I: In vitro findings. Biochem Pharmacol 51: 21-28
3. Churchill L, Graham AG, Shih C-K, Pauletti D, Farina PR, Grob PM (1996) Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacol 4: 125-135
4. Pairet M, Engelhardt G (1996) Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in-vivo of NSAIDs. In: Vane J, Botting J, Botting R (eds) Improved nonsteroid anti-inflammatory drugs - COX-2 enzyme inhibitors. Kluwer Academic Publishers, Dordrecht, pp 103-119
5. Distel M, Mueller C, Bluhmki E (1996) Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacol 4: 71-81
6. Anonymous (1988) Management of venous thromboembolism. Lancet 1: 275-277
7. Mirsen TR, Hachisnki VC (1988) Transient ischaemic attacks and stroke. Can Med Ass J 138: 1099-1105
8. Stein B, Fuster V (1989) Antithrombotic therapy in acute myocardial infarction: prevention of venous, left ventricular and coronary artery thromboembolism. Am J Cardiol 64: 33B-40B
9. Hirsh J (1991) Oral anticoagulant drugs. N Engl J Med 324: 1865-1875
10. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Roland M, Schary W (1974) Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 53: 1607-1617
11. 12C-pseudoracemates of warfarin in man. J Clin Invest 65: 746-753
12. Schulman S, Henriksson K (1989) Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol 28: 46-49
13. Stricker BH, Delhes JL (1982) Interaction between flurbiprofen and coumarins. BMJ 285: 1139
14. Serlin MJ, Breckenridge AM (1983) Drug interactions with warfarin. Drugs 25: 610-620
15. Verbeeck RK, Blackburn JL, Loewen GR (1983) Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs. Clin Pharmacokin 8: 297-331
16. Yacobi A, Levy G (1977) Protein binding of warfarin enantiomers in serum of humans and rats. J Pharmacokin Biopharm 5: 123-131
17. Verbeeck RK (1990) Pharmacokinetic drug interactions with nonsteroidal inflammatory drugs. Clin Pharmacokin 19: 44-66
18. Rolan PE (1994) Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 37: 125-128
19. O'Reilly RA, Trager WF, Motley CH, Howard W (1980) Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 28: 187-195
20. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF. Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF (1992) Hydroxylation of warfarin by human c-DNA expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 5: 54-59
21. Newlands AJ, Smith DA, Jones BC, Hawsworth GM (1992) Metabolism of nonsteroidal anti-inflammatory drugs by cytochrome P4502C. Br J Clin Pharmacol 34: 152P
22. Kondo M, Zhao J, Leeman T, Dayer P (1992) Biotransformation of oxicam NSAIDs by human cytochrome P450TB (CYP2C). Abstracts of the Vth world Conference on clinical pharmacology and therapeutics. Yokohama, Japan 243
23. Guengerich FP (1990) Mechanisms based inactivation of human liver microsomal cytochrome p-450 II A4 by gestodene. Chem Res Toxicol 3: 363-371
24. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome p-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423
25. Roden DM, Woosley RL (1983) Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide. disopyramide. Pharmacol Ther 23: 179-191
26. Andersen C, Balmer K, Lagerström PO (1993) Enantioselective assay of warfarin in blood plasma by liquid chromatography on Chiralcel OC. J Chromatogr 615: 159-163
27. Heinzel G, Woloszczak, Thomann R (1993) TopFit 2.0. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer, Stuttgart
28. Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29: 323-328
29. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M (1994) Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37: 563-569
30. Türck D, Busch U, Heinzel G, Narjes H (1996) Clinical pharmacokinetics of meloxicam. Br J Rheumatol 15 Suppl 1: 23-30
31. Eichler HG, Jung M, Kyrle PA, Rotter M, Korn A (1992) Absence of interaction between tenoxicam and warfarin. Eur J Clin Pharmacol 42: 227-229
32. Ravic M, Johnston A, Turner P (1990) Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgrad Med J 66 Suppl 4: S30-S34